Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to -$1.3 million.

  • NovaBay Pharmaceuticals' Cash from Financing Activities fell 16317.05% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 37749.23%. This contributed to the annual value of $1.5 million for FY2024, which is 2146.6% down from last year.
  • NovaBay Pharmaceuticals' Cash from Financing Activities amounted to -$1.3 million in Q3 2025, which was down 16317.05% from -$174000.0 recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Cash from Financing Activities registered a high of $14.8 million during Q4 2021, and its lowest value of -$1.7 million during Q1 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' median Cash from Financing Activities value was $96500.0 (recorded in 2021), while the average stood at $1.4 million.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Cash from Financing Activities soared by 29580000.0% in 2021 and then plummeted by 18609.72% in 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $14.8 million in 2021, then tumbled by 79.49% to $3.0 million in 2022, then plummeted by 100.86% to -$26000.0 in 2023, then surged by 2026.92% to $501000.0 in 2024, then tumbled by 363.27% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$174000.0 for Q2 2025, and -$1.7 million during Q1 2025.